Clinical Trial

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-02.
Trial Details
NCT Number NCT07451652
Lead Sponsor Hospital Universitario Dr. Jose E. Gonzalez
Conditions Relapsed/Refractory Diffuse Large B Cell Lymphoma
Enrollment 10 participants
Start Date 2026-03-17
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-01